Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies.Continue reading
Author Archive: Roxan Olivas
C-Path Appoints Biotech Executive and Investor Dr. Milad Alucozai to Board of Directors
TUCSON, Ariz., June 11, 2026 — Critical Path Institute® (C-Path) today announced the appointment of Milad Alucozai, DrPH, MPH, M.Sc., to its Board of Directors.Continue reading
C-Path Appoints Biotechnology Leader and Veteran Life-Science Attorney Yalonda Howze to Board of Directors
TUCSON, Ariz., June 10, 2026 — Critical Path Institute® (C-Path) today announced the appointment of Yalonda Howze, J.D., to its Board of Directors. Howze brings nearly two decades of executive leadership and legal experience across the biotechnology and life-science sectors, including her most recent current service as interim chief executive officer and president of Generation Bio.Continue reading
Critical Path Institute to Convene Drug Development Leaders at 2026 Global Impact Conference
Annual conference returns to Washington, D.C., Sept. 15-16; addresses challenges in establishing a new paradigm for how evidence of efficacy and safety is generated.Continue reading
Critical Path Institute Launches New Approach Methodologies Developer Coalition to Advance Human-Relevant Tools for Drug Development
Global coalition unites NAMs developers to accelerate validation, qualification, and regulatory adoption of human-relevant methodologies, reducing reliance on animal models and improving the efficiency of drug development.Continue reading
Critical Path Institute Awards $456,000 Grant to Advance Next-Generation Therapy for Rare Glycolipid Storage Disorders
TUCSON, Ariz., April 28, 2026 — Critical Path Institute® (C-Path) today announced a $456,000 grant to James Shayman, M.D., at the University of Michigan, to support development of a brain-penetrant therapy for glycosphingolipid storage disorders. Continue reading
AIRNA Joins C-Path’s Alpha-1 Antitrypsin Deficiency Consortium to Advance Innovative AATD Treatments
AIRNA, a clinical-stage company developing RNA-editing medicines with an initial focus on AATD, joins C-Path’s antitrypsin consortium upon initiation of its RepAIR1 global clinical study.Continue reading
Critical Path Institute Launches ‘One to Millions’ to Reshape the Future of Individualized Medicine at Global Scale
Global initiative to scale advanced therapeutic treatments to accelerate patient access worldwide.Continue reading
C-Path Taps Veteran Health Technology Leader to Drive Data and AI Strategy as Chief Data and Technology Officer
TUCSON, Ariz., March 24, 2026 — Critical Path Institute® (C-Path) today announced the appointment of Christopher Lunt as its Chief Data and Technology Officer. Lunt is a technology executive with more than 25 years of experience building large-scale data and analytics platforms across the federal government, Silicon Valley, and the healthcare sector. Continue reading
New Study on Early Parkinson’s Disease Progression Highlights Vital Role of Patient Focused Drug Development and Real-World Impacts
TUCSON, Ariz., March 10, 2026– Critical Path Institute® (C-Path) applauds the publication of a new study in the Journal of Neurology that offers critical longitudinal insights into how symptoms and functional impacts evolve for individuals with early Parkinson’s disease (PD).Continue reading